可注射型载阿霉素水凝胶治疗胶质瘤的实验研究

doi:10.20223/j.cnki.1000-8535.2025.05.006

广州医药 ›› 2025, Vol. 56 ›› Issue (5): 616-621.DOI: 10.20223/j.cnki.1000-8535.2025.05.006

可注射型载阿霉素水凝胶治疗胶质瘤的实验研究

李伟, 王业忠, 胡滨, 姬云翔, 柯炎斌

广州医科大学附属第二医院神经外科(广东广州 510260)

收稿日期:2024-08-22 出版日期:2025-05-20 发布日期:2025-06-17
通讯作者: 王业忠,E-mail：wangyz2008@126.com
基金资助:
广东省医学科研基金（A2023213）;广州市卫生健康科技一般引导项目（20221A011081）

Experimental study on the treatment of glioma with injectable doxorubicin hydrogel

LI Wei, WANG Yezhong, HU Bin, JI Yunxiang, KE Yanbin

Department of Neurosurgery,the Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510260,China

Received:2024-08-22 Online:2025-05-20 Published:2025-06-17

摘要/Abstract

摘要： 目的初步探讨可注射型载阿霉素水凝胶对胶质瘤的治疗作用。方法使用透析法检测载阿霉素水凝胶在体外释放药物的情况。构建大鼠皮下C6胶质瘤模型,按不同给药途径分为空白对照组、经静脉注射组、水凝胶组。给药15 h后,经免疫荧光检测阿霉素在肿瘤内部的分布情况。给药7 d后,计算出各组的抑瘤率;并对肿瘤组织进行苏木精-伊红染色。结果在体外,载阿霉素水凝胶具有缓释药物的性能。在体内,与经静脉给药相比,局部注射载阿霉素水凝胶使瘤内分布更多阿霉素,抑瘤率更高（42% vs 64%）,肿瘤细胞坏死更明显。结论载阿霉素水凝胶可为胶质瘤局部化学治疗提供新的载体。

关键词: 可注射型, 阿霉素, 水凝胶, 治疗, 胶质瘤

Abstract: Objective To investigate the therapeutic effect of injectable doxorubicin-containing hydrogel on glioma．Methods The release of doxorubicin hydrogel in vitro was detected by dialysis．The subcutaneous C6 glioma model of rats was constructed and divided into blank control group,intravenous injection group and hydrogel group according to different administration Methods．The distribution of doxorubicin in the tumor was detected by immunofluorescence 15 hours after administration．After 7 days of administration,the tumor inhibition rate of each group was calculated．The tumor tissue was stained with hematoxylin eosin． Results In vitro,doxorubicin-containing hydrogels had sustained drug release properties．In vivo,compared with intravenous administration,local injection of doxorubicin-containing hydrogel resulted in more doxorubicin distribution,higher tumor inhibition rate（42% vs 64%）and more obvious tumor cell necrosis．Conclusions Doxorubicin-containing hydrogel can provide a new carrier for local chemotherapy of glioma．

Key words: injectable, doxorubicin, hydrogel, treatment, glioma

李伟, 王业忠, 胡滨, 姬云翔, 柯炎斌. 可注射型载阿霉素水凝胶治疗胶质瘤的实验研究[J]. 广州医药, 2025, 56(5): 616-621.

LI Wei, WANG Yezhong, HU Bin, JI Yunxiang, KE Yanbin. Experimental study on the treatment of glioma with injectable doxorubicin hydrogel[J]. Guangzhou Medical Journal, 2025, 56(5): 616-621.

参考文献

[1] NIERENGARTEN M B.Global cancer statistics 2022:The report offers a view on disparities in the incidence and mortality of cancer by sex and region worldwide and on the areas needing attention[J].Cancer,2024,130(15):2568.
[2] POUYAN A,GHORBANLO M,ESLAMI M,et al.Glioblastoma multiforme:Insights into pathogenesis,key signaling pathways,and therapeutic strategies[J].Mol Cancer,2025,24(1):58.
[3] DI NUNNO V,FRANCESCHI E,TOSONI A,et al.Treatment of recurrent glioblastoma:State-of-the-art and future perspectives[J].Expert Rev Anticancer Ther,2020,20(9):785-795.
[4] SHERMAN J H,BOBAK A,ARSIWALA T,et al.Targeting drug resistance in glioblastoma(review)[J].Int J Oncol,2024,65(2):80.
[5] XIAO Y,GU Y,QIN L,et al.Injectable thermosensitive hydrogel-based drug delivery system for local cancer therapy[J].Colloids Surf B Biointerfaces,2021(200):111581.
[6] 王婷,杨铃,谢雨涵,等.持续释放CA4P和阿霉素的可注射水凝胶/短纤维复合物用于小鼠乳腺癌异种移植瘤联合化疗[J].南方医科大学学报,2022,42(5):625-632.
[7] FOURNIOLS T,RANDOLPH L D,STAUB A,et al.Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma[J].J Control Release,2015(210):95-104.
[8] PINEDA E,DOMENECH M,HERNÁNDEZ A,et al.Recurrent glioblastoma:Ongoing clinical challenges and future prospects[J].Onco Targets Ther,2023(16):71-86.
[9] PENA E S,GRAHAM-GURYSH E G,BACHELDER E M,et al.Design of biopolymer-based interstitial therapies for the treatment of glioblastoma[J].Int J Mol Sci,2021,22(23):13160.
[10] SUN Z,SONG C,WANG C,et al.Hydrogel-based controlled drug delivery for cancer treatment:A review[J].Mol Pharm,2020,17(2):373-391.
[11] SHADAB A,FAROKHI S,FAKOURI A,et al.Hydrogel-based nanoparticles:Revolutionizing brain tumor treatment and paving the way for future innovations[J].Eur J Med Res,2025,30(1):71.
[12] ZHOU X,HE X,SHI K,et al.Injectable thermosensitive hydrogel containing erlotinib-loaded hollow mesoporous silica nanoparticles as a localized drug delivery system for NSCLC therapy[J].Adv Sci(Weinh),2020,7(23):2001442.
[13] CHEN Y,DAI L,SHI K,et al.Cabazitaxel-loaded thermosensitive hydrogel system for suppressed orthotopic colorectal cancer and liver metastasis[J].Adv Sci(Weinh),2024,11(33):e2404800.
[14] PUENTE P,FETTIG N,LUDERER M J,et al.Injectable hydrogels for localized chemotherapy and radiotherapy in brain tumors[J].J Pharm Sci,2018,107(3):922-933.
[15] YE L,LV W,HE W,et al.Reduced malignant glioblastoma recurrence post-resection through the anti-CD47 antibody and Temozolomide co-embedded in-situ hydrogel system[J].J Control Release,2023(359):224-233.
[16] WANG X,YE L,HE W,et al.In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma[J].J Control Release,2022(345):786-797.
[17] HSU C Y,LIN J,WEI M F,et al.Local delivery of carboplatin-loaded hydrogel and calcium carbonate enables two-stage drug release for limited-dose radiation to eliminate mouse malignant glioma[J].Biomaterials,2025(312):122746.
[18] DONG Y,ZHANG J,WANG Y,et al.Intracavitary spraying of nanoregulator-encased hydrogel modulates cholesterol metabolism of glioma-supportive macrophage for postoperative glioblastoma immunotherapy[J].Adv Mater,2024,36(13):e2311109.
[19] CAO X,LI S,CHEN W,et al.Multifunctional hybrid hydrogel system enhanced the therapeutic efficacy of treatments for postoperative glioma[J].ACS Appl Mater Interfaces,2022,14(24):27623-27633.
[20] LONG W,LI S,YANG Y,et al.Self-cross-linked chitosan/albumin-bound nanoparticle hydrogel for inhibition of postsurgery malignant glioma recurrence.[J].ACS Appl Mater Interfaces,2023.

可注射型载阿霉素水凝胶治疗胶质瘤的实验研究

Experimental study on the treatment of glioma with injectable doxorubicin hydrogel

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	卢晓霞, 王佩, 王静喆. 免疫及靶向药物联合肝动脉灌注化疗治疗晚期肝癌的临床分析[J]. 广州医药, 2025, 56(5): 662-668.
[2]	杨佳林, 谢晓英. 双硫死亡与其他细胞死亡在卵巢癌治疗中的研究进展[J]. 广州医药, 2025, 56(4): 452-456.
[3]	刘静, 李敏, 潘亚雯, 周圆. 2型糖尿病合并骨质疏松的药物治疗进展[J]. 广州医药, 2025, 56(3): 316-322.
[4]	李兰英, 彭慧云, 江杰, 曾津, 胡宇敏, 方珊珊. 支气管镜联合雾化吸入药物对肺炎支原体肺炎患儿症状持续时间及肺部影像学好转情况分析[J]. 广州医药, 2025, 56(3): 377-381.
[5]	姚远, 尹亭亭. MDSCs在肿瘤免疫治疗中的研究进展[J]. 广州医药, 2025, 56(2): 151-159.
[6]	阮明辉, 姜龙, 辛宇, 邓强, 周一丁, 王刚. 浆细胞性乳腺炎的中西医结合治疗进展[J]. 广州医药, 2025, 56(1): 56-61.
[7]	吴刚, 赵海龙, 张生富, 马丽娟, 何煜洁, 郭斌. 浅析音乐疗法在儿童发育障碍疾病中的应用[J]. 广州医药, 2025, 56(1): 62-70.
[8]	高博, 陈家楠, 丘金城, 黄东生. 脊柱结核的外科治疗研究进展[J]. 广州医药, 2024, 55(9): 963-973.
[9]	易泽新, 伍勇. 弥漫性大B细胞淋巴瘤的放射治疗进展[J]. 广州医药, 2024, 55(9): 974-984.
[10]	刘丹丹, 曾麟娟, 陈维维, 涂堃琳, 袁娟. 基于CiteSpace的文献计量学分析近20年国内外音乐治疗焦虑研究热点的演化与趋势[J]. 广州医药, 2024, 55(7): 712-722.
[11]	张亚楠, 张永灿. 脑出血患者家属参与治疗共享决策满意度现状及影响因素分析[J]. 广州医药, 2024, 55(5): 535-540.
[12]	李儒雅, 梁亮, 周睿卿, 郝嘉懿, 阎文锦, 黄金棋, 王顺清. 血友病基因治疗国内外研究新进展[J]. 广州医药, 2024, 55(4): 331-341.
[13]	何丹, 成炜, 刘铭. 肿瘤可塑性与药物治疗抵抗[J]. 广州医药, 2024, 55(3): 213-220.
[14]	梁芳蓉, 杨蕊梦. MRI影像组学在胶质瘤术前分级预测中的研究进展[J]. 广州医药, 2024, 55(3): 221-230.
[15]	袁行勇, 姚春, 陈炜, 王晋平, 黄钰铧, 曲一荻, 曾汉林, 崔恩山, 廖雨芯. 阿尔茨海默病不同治疗方式研究新进展[J]. 广州医药, 2024, 55(3): 236-244.